CANCER OF UNKNOWN PRIMARY SITE
Clinical trials for CANCER OF UNKNOWN PRIMARY SITE explained in plain language.
Never miss a new study
Get alerted when new CANCER OF UNKNOWN PRIMARY SITE trials appear
Sign up with your email to follow new studies for CANCER OF UNKNOWN PRIMARY SITE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Genetic profiling may improve treatment for mysterious cancers
Disease control CompletedThis study tested whether using a patient's genetic profile to choose cancer treatment works better than standard chemotherapy for people with cancer of unknown primary site (CUP). About 529 adults whose cancer was controlled after initial chemo were randomly assigned to either p…
Matched conditions: CANCER OF UNKNOWN PRIMARY SITE
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 05:26 UTC
-
Immunotherapy shows promise for mysterious cancers
Disease control CompletedThis study tested the drug pembrolizumab in 35 people with cancer of unknown primary (CUP), a cancer that starts in an unknown location. The goal was to see if the drug could shrink tumors. Participants received pembrolizumab intravenously, and doctors measured tumor response usi…
Matched conditions: CANCER OF UNKNOWN PRIMARY SITE
Phase: PHASE2 • Sponsor: Imperial College London • Aim: Disease control
Last updated May 26, 2026 05:25 UTC
-
New drug shows promise for mysterious rare cancer
Disease control CompletedThis study tested a drug called sintilimab in people with a rare cancer where doctors cannot find where it started (cancer of unknown primary). Ten participants received the drug every three weeks. The goal was to see if the drug could shrink tumors or slow the cancer. The study …
Matched conditions: CANCER OF UNKNOWN PRIMARY SITE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:25 UTC